GlaxoSmithKline Plc will pay nearly $41 million to 37 U.S. states and the District of Columbia to settle allegations related to faulty drug manufacturing processes at a former factory in Puerto Rico. Under terms of the pact announced Thursday with Glaxo and its SB Pharmco Puerto Rico Inc unit, each state will share in the total settlement payout. The settlement follows a related $750 million payment that the British drugmaker said it would make as part of a plea agreement with the U.S. Department of Justice last year.
